PMCID:PMC3532946īarry ER, Morikawa T, Butler BL, Shrestha K, de la Rosa R, Yan KS, Fuchs CS, Magness ST, Smits R, Ogino S, Kuo CJ, Camargo FD. Aspirin use, tumor PIK3CA mutation status, and colorectal-cancer survival. Liao X, Lochhead P, Nishihara R, Morikawa T, Kuchiba A, Yamauchi M, Imamura Y, Qian ZR, Baba Y, Shima K, Sun R, Nosho K, Meyerhardt JA, Giovannucci E, Fuchs CS, Chan AT, Ogino S. Tumor microenvironment contributes to innate RAF-inhibitor resistance through HGF secretion. Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J, Davis A, Mongare MM, Gould J, Frederick DT, Cooper ZA, Chapman PB, Solit DB, Ribas A, Lo RS, Flaherty KT, Ogino S, Wargo JA, Golub TR. Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. Yamauchi M, Morikawa T, Kuchiba A, Imamura Y, Qian ZR, Nishihara R, Liao X, Waldron L, Hoshida Y, Huttenhower C, Chan AT, Giovannucci E, Fuchs CS, Ogino S. Association of CTNNB1 (β-catenin) alterations, body mass index, and physical activity with survival in patients with colorectal cancer. Morikawa T, Kuchiba A, Yamauchi M, Meyerhardt JA, Shima K, Nosho K, Chan AT, Giovannucci E, Fuchs CS, Ogino S. Aspirin use and survival after diagnosis of colorectal cancer. Aspirin use and risk of colorectal cancer according to cyclooxygenase-2 expression. My publication list can also be found at Ĭhan AT, Ogino S, Fuchs CS. Publications at Pubmed Central (full text freely available):Ĭlarivate Analytics / Web of Science (formerly, Thomson Reuters) has determined me as one of the “Most Influential Scientific Minds: 2014” and one of the “Highly Cited Researchers” in 2015, 2016, 2017, 2018, 2019, 2020, 2021, 2022. Publications at Pubmed (this misses some papers with only my first initial S Ogino as my name).Ĭitation records at Google Scholars (over 55,00 citations and h-index of 121 as of November 2022) I have published 40 other peer-reviewed articles, many of which have introduced novel concepts, paradigms, theories, and research frameworks related to MPE (listed below). I do not intend to use it as a definitive metric of quality of any given journal.) (Impact Factor is used merely for convenience. A number of papers have been published in high-impact journals with Impact Factor >20 (New England Journal of Medicine, Nature, Nature Genetics, Nature Reviews Clinical Oncology, JAMA, JAMA Oncology, Journal of Clinical Oncology, Annals of Oncology, Gastroenterology, Gut, Science Translational Medicine, etc.). As of November 2022, I have published >400 original articles and new concept papers, among which I am the first, last or co-last author in about 50% of papers.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |